Cargando…
Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study
Background. The so-called “vaccine hesitancy” still represents a common phenomenon that undermines the effectiveness of vaccination campaigns. In 2020, the Italian Medicines Agency recommended to bring forward the flu vaccination campaign, whose importance was also emphasized for patients with Multi...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301852/ https://www.ncbi.nlm.nih.gov/pubmed/34356125 http://dx.doi.org/10.3390/brainsci11070890 |
_version_ | 1783726767149678592 |
---|---|
author | Ziello, Antonio Scavone, Cristina Di Battista, Maria Elena Salvatore, Simona Di Giulio Cesare, Daniele Moreggia, Ornella Allegorico, Lia Sagnelli, Anna Barbato, Stefano Manzo, Valentino Capuano, Annalisa Maniscalco, Giorgia Teresa |
author_facet | Ziello, Antonio Scavone, Cristina Di Battista, Maria Elena Salvatore, Simona Di Giulio Cesare, Daniele Moreggia, Ornella Allegorico, Lia Sagnelli, Anna Barbato, Stefano Manzo, Valentino Capuano, Annalisa Maniscalco, Giorgia Teresa |
author_sort | Ziello, Antonio |
collection | PubMed |
description | Background. The so-called “vaccine hesitancy” still represents a common phenomenon that undermines the effectiveness of vaccination campaigns. In 2020, the Italian Medicines Agency recommended to bring forward the flu vaccination campaign, whose importance was also emphasized for patients with Multiple Sclerosis (MS). We aimed to assess vaccination behavior in patients with MS to prepare for the upcoming SARS-CoV-2 vaccination challenge. Methods. This is an observational study carried out in one MS clinical Centre that enrolled all MS patients who were eligible for any of the flu vaccines recommended by the Italian medicines Agency. Results. 194 patients were enrolled. Patients’ mean age was 43.9 years and 66% were female. Comorbidities, mainly represented by non-autoimmune diseases, were identified in 52% of patients. Almost all patients were receiving a DMT during the study period, mainly dimethyl fumarate, natalizumab, teriflunomide, and interferon. Out of 194 patients, 58.2% accepted to be vaccinated. No statistically significant differences were found, except for the use of natalizumab, which was higher among vaccinated patients. Conclusion. The results of our study emphasize the importance of education and communication campaigns addressed both to healthcare providers and patients with MS, especially considering that MS patients are currently receiving COVID-19 vaccinations. |
format | Online Article Text |
id | pubmed-8301852 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83018522021-07-24 Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study Ziello, Antonio Scavone, Cristina Di Battista, Maria Elena Salvatore, Simona Di Giulio Cesare, Daniele Moreggia, Ornella Allegorico, Lia Sagnelli, Anna Barbato, Stefano Manzo, Valentino Capuano, Annalisa Maniscalco, Giorgia Teresa Brain Sci Article Background. The so-called “vaccine hesitancy” still represents a common phenomenon that undermines the effectiveness of vaccination campaigns. In 2020, the Italian Medicines Agency recommended to bring forward the flu vaccination campaign, whose importance was also emphasized for patients with Multiple Sclerosis (MS). We aimed to assess vaccination behavior in patients with MS to prepare for the upcoming SARS-CoV-2 vaccination challenge. Methods. This is an observational study carried out in one MS clinical Centre that enrolled all MS patients who were eligible for any of the flu vaccines recommended by the Italian medicines Agency. Results. 194 patients were enrolled. Patients’ mean age was 43.9 years and 66% were female. Comorbidities, mainly represented by non-autoimmune diseases, were identified in 52% of patients. Almost all patients were receiving a DMT during the study period, mainly dimethyl fumarate, natalizumab, teriflunomide, and interferon. Out of 194 patients, 58.2% accepted to be vaccinated. No statistically significant differences were found, except for the use of natalizumab, which was higher among vaccinated patients. Conclusion. The results of our study emphasize the importance of education and communication campaigns addressed both to healthcare providers and patients with MS, especially considering that MS patients are currently receiving COVID-19 vaccinations. MDPI 2021-07-05 /pmc/articles/PMC8301852/ /pubmed/34356125 http://dx.doi.org/10.3390/brainsci11070890 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ziello, Antonio Scavone, Cristina Di Battista, Maria Elena Salvatore, Simona Di Giulio Cesare, Daniele Moreggia, Ornella Allegorico, Lia Sagnelli, Anna Barbato, Stefano Manzo, Valentino Capuano, Annalisa Maniscalco, Giorgia Teresa Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study |
title | Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study |
title_full | Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study |
title_fullStr | Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study |
title_full_unstemmed | Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study |
title_short | Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study |
title_sort | influenza vaccine hesitancy in patients with multiple sclerosis: a monocentric observational study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301852/ https://www.ncbi.nlm.nih.gov/pubmed/34356125 http://dx.doi.org/10.3390/brainsci11070890 |
work_keys_str_mv | AT zielloantonio influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy AT scavonecristina influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy AT dibattistamariaelena influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy AT salvatoresimona influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy AT digiuliocesaredaniele influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy AT moreggiaornella influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy AT allegoricolia influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy AT sagnellianna influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy AT barbatostefano influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy AT manzovalentino influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy AT capuanoannalisa influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy AT maniscalcogiorgiateresa influenzavaccinehesitancyinpatientswithmultiplesclerosisamonocentricobservationalstudy |